Fueling Tomorrow’s Breakthrough Therapies Through the Power of Data at Scale
Genomics – and single-cell ribonucleic acid sequencing (scRNAseq) in particular – continue to play an increasingly vital role in the discovery of novel drugs and vaccines. Sequencing RNA provides fundamental insights into the regulation of genomes. Interpreting large-scale, complex transcriptomics data is critically important to understanding the molecular and cellular basis of disease.
“Data analytics and insights, powered by artificial intelligence and machine learning, are key to speed and innovation,” says Lidia Fonseca, Chief Digital and Technology Officer, Pfizer.
Pfizer has been on the leading edge of innovation, leveraging large scale data and advanced technology platforms to fuel tomorrow’s breakthrough therapies.
Pfizer has developed a state-of-the-art supercomputing center that is being used by our scientists to accelerate our research and development efforts. Researchers have run large scale models and simulations to predict the structure of COVID-19 oral candidates, optimize mRNA manufacturing processes, improve storage stability of mRNA vaccine, and create scientific images and documents for U.S. Food and Drug Administration (FDA) filings.
In addition, this year, Pfizer partnered with Seven Bridges, an industry-leading bioinformatics provider, to support the development of a scRNAseq data management and collaboration solution, which carries a very large data footprint. In combination with Pfizer’s cloud-based environment, research teams can analyze, compute and interpret large scale data sets to conduct bioinformatic analyses that support clinical discovery efforts.
This partnership underscores the growing importance of efficient genomic data management, visibility and retrieval. The agreement is introducing avenues to expand Pfizer’s cloud platforms and capabilities, a key component of Pfizer’s integrated digital cloud and advanced analytics strategy.
Pfizer’s evolving capabilities and partnerships are maximizing the value of our data and empowering Pfizer to accelerate the delivery of breakthroughs that change patients’ lives.